Organigram Holdings Partners with 4C LABS to Supply Medical Cannabis to the UK

LOS ANGELES— Organigram Holdings Inc., a recognized licensed producer of cannabis, announced today its strategic expansion into the UK market. The company has inked a supply agreement with 4C LABS, an emerging healthcare, tech, and pharmaceutical firm. This collaboration focuses on the virtual prescription, distribution, and clinical enhancement of cannabis-infused products for human health in the United Kingdom.

Medical cannabis has had legal status in the UK since 2018. However, the British market faces challenges in maintaining consistent, premium-grade cannabis supplies. This is due in part to the substantial energy cost disparities when juxtaposed with Canadian operations. Beena Goldenberg, Organigram’s Chief Executive Officer, commented, “With the UK grappling with such constraints, importing medical cannabis emerges as a lucrative solution to cater to this expanding demographic.” She expressed Organigram’s enthusiasm in partnering with 4C LABS, aiming to augment the accessibility of medical cannabis for UK beneficiaries.

4C LABS, with its commitment to rendering a unique value proposition to its UK clientele, emphasizes premium-grade products, competitive pricing, a robust supply chain, and unparalleled customer service. Greg Dobbin, CEO of 4C LABS, expressed his excitement, stating, “Introducing Organigram’s offerings to the UK and Channel Islands aligns seamlessly with our objectives.”

The successful execution of activities stipulated in the Agreement remains contingent on adhering to all relevant legal frameworks. This includes obtaining periodic approvals from Health Canada, the UK Medicines and Healthcare Products Regulatory Agency, and other pertinent regulatory bodies.